Pulse Biosciences (NASDAQ:PLSE) Trading Up 5.3% – Here’s What Happened

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s share price rose 5.3% on Tuesday . The stock traded as high as $20.54 and last traded at $20.18. Approximately 20,155 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 200,547 shares. The stock had previously closed at $19.17.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research note on Thursday, December 12th.

Pulse Biosciences Price Performance

The firm has a 50-day moving average price of $17.74 and a 200-day moving average price of $16.50.

Pulse Biosciences (NASDAQ:PLSE) last issued its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same period last year, the firm earned ($0.19) EPS.

Insider Buying and Selling at Pulse Biosciences

In other Pulse Biosciences news, Director Robert W. Duggan bought 56,054 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was acquired at an average price of $17.35 per share, with a total value of $972,536.90. Following the transaction, the director now owns 42,228,057 shares in the company, valued at $732,656,788.95. This represents a 0.13 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 71.50% of the company’s stock.

Institutional Trading of Pulse Biosciences

Large investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. lifted its position in Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after purchasing an additional 97,565 shares during the period. Creative Planning raised its stake in Pulse Biosciences by 113.9% during the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after buying an additional 11,667 shares during the last quarter. Cetera Advisors LLC bought a new position in shares of Pulse Biosciences during the 1st quarter valued at $109,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Pulse Biosciences in the 1st quarter worth $88,000. Finally, Quest Partners LLC bought a new stake in shares of Pulse Biosciences in the second quarter worth $91,000. 76.95% of the stock is currently owned by institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.